

<b>POLICY NAME</b>	Dalfampridine	<b>POLICY #</b>	1854P
--------------------	---------------	-----------------	-------

## Criteria

### Coverage Criteria

- ☐ 1.1 Diagnosis of multiple sclerosis (MS) Prescribed by a neurologist (nervous system doctor)
- ☐ 1.2 Patient must be 18 years of age or older
- ☐ 1.3 Ambulatory (able to walk)
- ☐ 1.4 No history of seizures
- ☐ 1.5 25-foot walk Test Completion
  - Initial coverage: Member has completed two (2) in office 25-foot timed walk tests (with no more than five (5) minute break between tests) AND the average time is submitted as baseline
  - Continued coverage: Member has achieved a 20% decrease in time to walk 25 feet from baseline while on treatment with Ampyra
  - All walk tests must be conducted in office by ordering prescriber
- ☐ 1.6 Documentation that patients with relapsing-remitting multiple sclerosis are on concurrent therapy with a disease modifying agent (such as Aubagio)

### Authorization Criteria

- ☐ 2.1 Initial approval: 12 months
- ☐ 2.2 Subsequent approvals: 12 months approval based on therapeutic response defined as at least a 20% decrease in the average 25 foot walk test time compared to baseline

### Discontinuation Criteria

- ☐ 3.1 Experience a seizure, OR
- ☐ 3.2 Kidney impairment with a creatinine clearance less than ( < ) 80mL/min, OR
- ☐ 3.3 Wheelchair bound Criteria References